CGM Adherence Compared to Finger-stick Glucose Monitoring in Pregnancies With Type 2 Pregestational Diabetes

Recruiting

Maternal Continuous Glucose Monitoring Surveillance Compared to Finger-stick Glucose Monitoring in Pregnancies With Type 2 Pregestational Diabetes

Who can join

Ages 18 and older · Women

Full eligibility criteria

Inclusion Criteria:

* singleton pregnancies
* fetuses without anomalies
* diagnosis of Type 2 diabetes
* initiation of prenatal care at \<20 weeks gestation

Exclusion Criteria:

* diagnosis of Type 1 diabetes
* allergy to insulin
* inability to wear a continuous glucose monitor

About the study

The purpose of this study is to compare patient adherence to blood sugar monitoring during pregnancy using two different measurement methods in pregnancies complicated by pregestational type 2 diabetes (T2DM). Pregnant patients with T2DM are at risk of having larger babies, babies with low sugar levels in the first 24 hours of life, higher rates of cesarean delivery, stillbirth (death of baby inside the womb), and hypertensive or high blood pressure disorders of pregnancy, such as preeclampsia. Prior studies have shown that treating high blood sugars in pregnancy with medications can reduce these risks. To determine the amount of medication needed, recording of blood sugar levels is necessary. This trial aims to determine whether continuous blood sugar monitors have improved patient recording of blood sugar levels over finger stick blood sugar measurements.

Patients involved in the study will be assigned to either:

1. Fingerstick glucose monitoring (FSG) 2. Continuous glucose monitoring (CGM)

Patients will be randomize in a 1:1 ratio.

FSG Group: blood sugar is tested four times daily - once fasting and two hours after every meal (post-prandial). Blood will be tested using a glucometer, and values will be recorded in a blood sugar log from the time of enrollment to the time of delivery.

CGM Group: A CGM sensor will be placed on the patient's arm for blood sugar collection every 3-5 minutes. This data is sent to a phone application from the time of enrollment to the time of delivery. These sensors will need to be replaced every 14 days.

Percent adherence will be recorded from the time you were randomized to a study group until delivery.

What is being tested

Continuous glucose monitor (device)
Glucometer (device)

Sponsor: Thomas Jefferson University · Participants: 70 · Started: Oct 1, 2025

Contact the study team

Brandy Firman · Phone: 215-955-8401

Official record on ClinicalTrials.gov — NCT07184775

Locations in the U.S.

New Jersey	Jefferson Health New Jersey, Sewell
Pennsylvania	Thomas Jefferson University, Philadelphia

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.